Genetic Analysis Points to Potential Role for Aspirin in Personalized Dementia Prevention
A new genetic analysis led by researchers at Monash University suggests that low-dose aspirin could significantly lower the risk of dementia for older individuals with a specific genetic profile. Published in the journal Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, the study analyzed genetic data from more than 13,500 participants in the landmark ASPREE (Aspirin in Reducing Events in the Elderly) Trial to determine if a person’s genes influence how aspirin affects their cognitive health over time.
Unlocking a Targeted Approach Through Genetics
While previous large-scale clinical trials have concluded that daily aspirin does not generally prevent dementia when evaluated across an entire population, this latest study indicates that broader generalizations might overlook targeted benefits for specific subgroups. The research team screened polygenic scores across the cohort to evaluate whether genetic markers tied to various biological functions altered the outcomes of aspirin use.
The investigation revealed a striking association tied specifically to genes that influence platelet count. Investigators categorized participants based on their platelet-related genetic scores. Among the participants who fell into the highest 20% of these scores, only 1.0% of those taking low-dose aspirin developed dementia, compared to 3.3% of those who received a placebo. This translates to an approximate 70% lower relative risk of developing dementia for individuals in this particular genetic bracket who took the medication.
Weighing Significant Risks and Benefits
Despite the promising reduction in dementia risk among the genetically identified subgroup, the researchers emphasize that aspirin therapy carries serious medical drawbacks that must be carefully managed. The same analysis showed that aspirin significantly increased the incidence of major bleeding events within this high-scoring group.
According to the findings, major bleeding occurred in 4.4% of participants taking aspirin who possessed the high platelet-count genetic scores, compared to just 2.1% of those receiving the placebo. This elevated risk of hemorrhage underscores why medical professionals urge caution regarding broad interpretations of the data.
Lead author Dr. Peter Fransquet, a research fellow at Monash University’s School of Public Health and Preventive Medicine, explained that the discovery shifts attention toward underlying biological mechanisms. Unlike prior investigations, the signaling observed in this analysis was not linked to established genetic risk factors traditionally associated with Alzheimer’s disease and other forms of dementia. Instead, it directs scientific focus squarely toward platelet biology as a fresh avenue for exploration.
Looking Toward Future Trials
Experts stress that the findings are preliminary and require rigorous validation. Medical authorities strongly advise that older adults should not begin taking aspirin for the purpose of preventing cognitive decline without direct consultation with their healthcare providers, particularly given the documented hazards associated with internal bleeding.
With public health projections estimating that hundreds of thousands of individuals live with cognitive decline globally—a figure expected to scale significantly in the coming decades—researchers hope that personalized medicine will eventually replace one-size-fits-all strategies. If future clinical trials specifically designed for individuals with this platelet-related genetic profile confirm the results, the widespread availability and low cost of aspirin could eventually help shape targeted preventative care.
Source: Medical Xpress
